https://www.pharmaradar360.com/article/weekly-buzz-jnj-wins-fda-nod-axgn-hcwb-strike-deals-roiv-azn-gpcr-lead-clinical-30dd4ea925537eabPharmaRadar360en2026-09-11T16:06:00.000ZWeekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trialshttps://www.pharmaradar360.com/article/psychedelics-are-on-the-fda-s-mind-098b13158b5d2c80PharmaRadar360en2026-09-11T16:04:32.000ZPsychedelics are on the FDA’s mindhttps://www.pharmaradar360.com/article/fda-extends-review-of-exelixis-colorectal-cancer-drug-candidate-2245083406727d54PharmaRadar360en2026-09-11T16:02:00.000ZFDA extends review of Exelixis’ colorectal cancer drug candidatehttps://www.pharmaradar360.com/article/clarity-on-ai-responsibilities-in-healthcare-needed-national-commission-says-9f92ea5d94637140PharmaRadar360en2026-09-11T15:52:10.000ZClarity on AI responsibilities in healthcare needed, National Commission sayshttps://www.pharmaradar360.com/article/pharmtech-weekly-roundup-september-11-2026-86af1c68f7295979PharmaRadar360en2026-09-11T15:47:46.000ZPharmTech Weekly Roundup—September 11, 2026https://www.pharmaradar360.com/article/top-biotech-picks-from-needham-company-for-second-half-of-2026-ee74fb0087d5cc48PharmaRadar360en2026-09-11T15:44:15.000ZTop Biotech Picks From Needham & Company for Second Half of 2026https://www.pharmaradar360.com/article/south-korea-s-drug-safety-agency-worse-than-1960s-fda-d3716d4263c37159PharmaRadar360en2026-09-11T15:43:25.000ZSouth Korea's Drug Safety Agency Worse Than 1960s FDAhttps://www.pharmaradar360.com/article/gregg-gorniak-what-changed-in-five-years-of-dscsa-ca123a64e61f2012PharmaRadar360en2026-09-11T15:40:17.000ZGregg Gorniak: What Changed in Five Years of DSCSA?https://www.pharmaradar360.com/article/simultaneous-anaerobic-bioreactor-could-accelerate-sustainable-biomanufacturing-ae1dbbfbb1b962fdPharmaRadar360en2026-09-11T15:36:09.000ZSimultaneous anaerobic bioreactor could accelerate sustainable biomanufacturinghttps://www.pharmaradar360.com/article/duopharma-biotech-detects-unauthorised-system-access-attempt-01f83664a547773aPharmaRadar360en2026-09-11T15:27:06.000ZDuopharma Biotech Detects Unauthorised System Access Attempthttps://www.pharmaradar360.com/article/news-by-cnbc-tv18-on-tradingview-2026-09-11-cnbctv-df10e080b094b-0-4a5c05ed391864b9PharmaRadar360en2026-09-11T15:17:33.000ZNews by CNBC TV18 on TradingView, 2026-09-11 — cnbctv:df10e080b094b:0https://www.pharmaradar360.com/article/sex-ratios-at-birth-in-the-uk-2018-to-2022-7dbac71278ce6443PharmaRadar360en2026-09-11T15:09:30.000ZSex ratios at birth in the UK: 2018 to 2022https://www.pharmaradar360.com/article/working-for-dhsc-7fde6c0568507ce7PharmaRadar360en2026-09-11T14:39:07.000ZWorking for DHSChttps://www.pharmaradar360.com/article/decision-orphan-registered-medicinal-products-39e75e2ced1518f0PharmaRadar360en2026-09-11T14:20:39.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/fda-expands-hyrnuo-use-in-her2-mutated-lung-cancer-c8473990dcc2cb27PharmaRadar360en2026-09-11T14:14:00.000ZFDA Expands Hyrnuo Use in HER2-Mutated Lung Cancerhttps://www.pharmaradar360.com/article/advanced-therapy-medicinal-products-regulation-and-licensing-in-uk-59aee4b062d03eb4PharmaRadar360en2026-09-11T14:11:00.000ZAdvanced therapy medicinal products: regulation and licensing in UKhttps://www.pharmaradar360.com/article/why-pharma-s-next-ai-challenge-is-supervision-not-adoption-627d3deb812bd7ddPharmaRadar360en2026-09-11T14:09:06.000ZWhy Pharma's Next AI Challenge Is Supervision, Not Adoptionhttps://www.pharmaradar360.com/article/watch-conversations-on-america-s-global-biotech-leadership-0e8139d8aefabfa4PharmaRadar360en2026-09-11T14:04:23.000ZWATCH: Conversations on America's global biotech leadershiphttps://www.pharmaradar360.com/article/the-future-of-ras-inhibitors-b9331991fc80225fPharmaRadar360en2026-09-11T13:48:47.000ZThe future of RAS inhibitorshttps://www.pharmaradar360.com/article/how-pharmaceutical-logistics-comes-together-d3a682022830edcePharmaRadar360en2026-09-11T13:47:07.000ZHow Pharmaceutical Logistics Comes Togetherhttps://www.pharmaradar360.com/article/5-things-to-know-in-life-sciences-week-of-sept-7-2026-421ed658cac3010fPharmaRadar360en2026-09-11T13:45:39.000Z5 things to know in life sciences: Week of Sept. 7, 2026https://www.pharmaradar360.com/article/pneumococcal-disease-cases-caused-by-serotypes-not-covered-by-pcv13-ce6e5496ced9fd89PharmaRadar360en2026-09-11T13:42:47.000ZPneumococcal disease: cases caused by serotypes not covered by PCV13https://www.pharmaradar360.com/article/pneumococcal-disease-cases-caused-by-serotypes-covered-by-pcv13-2ddf38f53562a4bdPharmaRadar360en2026-09-11T13:42:16.000ZPneumococcal disease: cases caused by serotypes covered by PCV13https://www.pharmaradar360.com/article/cancer-drug-shortages-keep-disrupting-patient-care-6e2e3af5fd0b345dPharmaRadar360en2026-09-11T13:41:13.000ZCancer drug shortages keep disrupting patient carehttps://www.pharmaradar360.com/article/novo-holdings-and-leading-international-funds-are-investing-nearly-dkk-60m-in-a-7baec2cae950d5a3PharmaRadar360en2026-09-11T13:29:00.000ZNovo Holdings and leading international funds are investing nearly DKK 60m in a new Danish biotech companyhttps://www.pharmaradar360.com/article/top-investor-urges-novartis-for-stronger-acquisition-oversight-after-m-a-and-tri-75168779bfdde9caPharmaRadar360en2026-09-11T13:28:54.000ZTop Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbackshttps://www.pharmaradar360.com/article/ers-2026-bmi-type-2-inflammation-and-asthma-attack-risk-3aedc94d1f105adaPharmaRadar360en2026-09-11T13:08:06.000ZERS 2026: BMI, type-2 inflammation, and asthma attack riskhttps://www.pharmaradar360.com/article/new-light-emitting-nanoparticles-can-detect-subtle-chemical-differences-to-enhan-67d29ed1f086abd0PharmaRadar360en2026-09-11T13:01:41.000ZNew light-emitting nanoparticles can detect subtle chemical differences to enhance pharmaceutical manufacturing, pollution prevention and morehttps://www.pharmaradar360.com/article/lundbeck-drug-candidate-granted-another-us-fda-designation-9f040c75940d5b94PharmaRadar360en2026-09-11T13:00:53.000ZLundbeck drug candidate granted another US FDA designationhttps://www.pharmaradar360.com/article/14-l156-d-bio-organic-apple-peach-mango-6-months-lupilu-94ba913aacaf92bbPharmaRadar360en2026-09-11T12:52:25.000ZΑνάκληση του αριθμού παρτίδας 14 L156 D της βρεφικής τροφής με ονομασία πώλησης “Bio/Organic Apple-Peach-Mango, 6+ months” και εμπορική ονομασία “LUPILU”https://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-550b955b3ef9248aPharmaRadar360en2026-09-11T12:39:47.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/india-s-biotech-growth-needs-more-long-term-capital-says-expert-b0d7e83756aece93PharmaRadar360en2026-09-11T12:31:33.000ZIndia’s biotech growth needs more long-term capital, says experthttps://www.pharmaradar360.com/article/singapore-launches-biotech-focused-boston-hub-to-build-on-centuries-old-bond-b89995faef2f0ae8PharmaRadar360en2026-09-11T12:30:00.000ZSingapore launches biotech-focused Boston hub to build on 'centuries-old bond'https://www.pharmaradar360.com/article/frazier-adds-1-1b-to-small-and-mid-sized-biotech-fund-ee5879e810cd4a42PharmaRadar360en2026-09-11T12:29:58.000ZFrazier adds $1.1B+ to small and mid-sized biotech fundhttps://www.pharmaradar360.com/article/kenya-s-wealthy-merali-family-acquires-stake-in-pharmaceutical-glass-plant-0ddbfae56327c1a6PharmaRadar360en2026-09-11T12:26:04.000ZKenya's wealthy Merali family acquires stake in pharmaceutical glass planthttps://www.pharmaradar360.com/article/eppendorf-launches-refrigerated-centrifuge-5811-r-aaa328684245d693PharmaRadar360en2026-09-11T12:19:54.000ZEppendorf launches refrigerated Centrifuge 5811 Rhttps://www.pharmaradar360.com/article/report-an-outbreak-of-acute-respiratory-infection-in-an-adult-social-care-settin-4b8ec42924935cd1PharmaRadar360en2026-09-11T12:14:06.000ZReport an outbreak of acute respiratory infection in an adult social care settinghttps://www.pharmaradar360.com/article/should-you-bet-big-on-drugmakers-vaneck-pharmaceutical-etf-vs-invesco-healthcare-6bf4962a35aab8acPharmaRadar360en2026-09-11T12:13:54.000ZShould You Bet Big on Drugmakers? VanEck Pharmaceutical ETF vs. Invesco Healthcare ETF Compared.https://www.pharmaradar360.com/article/the-download-biotech-s-future-and-cheaper-cleaner-steel-69a3d6cc2f2a0a2fPharmaRadar360en2026-09-11T12:10:00.000ZThe Download: biotech’s future and cheaper, cleaner steelhttps://www.pharmaradar360.com/article/sterlitech-launches-benchtop-membrane-filtration-systems-4c0ec37e526d2019PharmaRadar360en2026-09-11T12:03:57.000ZSterlitech launches benchtop membrane filtration systemshttps://www.pharmaradar360.com/article/profitable-biotech-incyte-forms-handle-as-institutional-buyers-load-up-on-stock-e395f7467425a742PharmaRadar360en2026-09-11T12:00:00.000ZProfitable Biotech Incyte Forms Handle As Institutional Buyers Load Up On Stockhttps://www.pharmaradar360.com/article/transition-of-the-icelandic-medicines-agency-s-website-in-full-swing-c750fd2961bf03e7PharmaRadar360en2026-09-11T11:59:00.000ZTransition of the Icelandic Medicines Agency’s Website in Full Swinghttps://www.pharmaradar360.com/article/mrna-cancer-vaccines-biggest-barriers-to-market-a1a5e5c1027f15daPharmaRadar360en2026-09-11T11:56:12.000ZmRNA cancer vaccines’ biggest barriers to markethttps://www.pharmaradar360.com/article/u-s-fda-extends-review-of-exelixis-cancer-drug-deaffdf4f5a748a4PharmaRadar360en2026-09-11T11:49:56.000ZU.S. FDA extends review of Exelixis’ cancer drughttps://www.pharmaradar360.com/article/fda-extends-review-timeline-for-exelixis-cancer-drug-19d15b23009bb8c7PharmaRadar360en2026-09-11T11:33:41.000ZFDA Extends Review Timeline for Exelixis Cancer Drughttps://www.pharmaradar360.com/article/frost-sullivan-presents-the-global-gene-therapy-crdmo-technology-innovation-lead-05419dc90ac4e4e3PharmaRadar360en2026-09-11T11:28:00.000ZFrost & Sullivan presents the "GLOBAL GENE THERAPY CRDMO TECHNOLOGY INNOVATION LEADERSHIP AWARD" to PackGene Biotech Inc.https://www.pharmaradar360.com/article/staunch-biotech-competition-spurs-new-secretive-tactics-shifts-investor-approach-bef2c24268292855PharmaRadar360en2026-09-11T10:37:52.000ZStaunch biotech competition spurs new secretive tactics, shifts investor approachhttps://www.pharmaradar360.com/article/the-early-scale-cpc-biotech-and-multiply-labs-smoothen-cell-therapy-automation-b-cb9bcf29049b507aPharmaRadar360en2026-09-11T10:27:42.000ZThe Early Scale: CPC Biotech and Multiply Labs smoothen cell therapy automation bottleneckhttps://www.pharmaradar360.com/article/shanghai-henlius-biotech-says-nda-for-120-mg-biosimilar-denosumab-hlx14-accepted-c33c1fb7dab637a0PharmaRadar360en2026-09-11T10:26:44.000ZShanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPAhttps://www.pharmaradar360.com/article/mrkon-risks-explained-keytruda-dependence-patent-expiry-clinical-trials-and-toke-0f495729ddaa03b6PharmaRadar360en2026-09-11T10:21:13.000ZMRKON Risks Explained: KEYTRUDA Dependence, Patent Expiry, Clinical Trials and Tokenized Stock Riskhttps://www.pharmaradar360.com/article/poland-s-case-against-eu-wastewater-rules-boosted-by-advocate-general-opinion-0cb3bd178f9e4c11PharmaRadar360en2026-09-11T10:18:25.000ZPoland's case against EU wastewater rules boosted by Advocate General opinionhttps://www.pharmaradar360.com/article/angelman-drug-partner-for-research-alliance-iii-racc-eyes-2029-data-6f76cf896ec6330ePharmaRadar360en2026-09-11T10:04:55.000ZAngelman drug partner for Research Alliance III (RACC) eyes 2029 datahttps://www.pharmaradar360.com/article/estates-safety-fund-initial-schemes-and-associated-funding-allocations-2026-to-2-578511fd55580096PharmaRadar360en2026-09-11T09:54:19.000ZEstates Safety Fund: initial schemes and associated funding allocations, 2026 to 2030https://www.pharmaradar360.com/article/set-yourself-up-for-a-strong-2027-2-pharmaceutical-stocks-to-buy-in-september-7c5df69ea3cb3fa3PharmaRadar360en2026-09-11T09:53:27.000ZSet Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in Septemberhttps://www.pharmaradar360.com/article/from-tartan-army-to-biotech-deepening-scotland-s-ties-with-boston-through-new-li-882a8830a7c1ede8PharmaRadar360en2026-09-11T09:40:13.000ZFrom Tartan Army to biotech – deepening Scotland’s ties with Boston through new life sciences partnershiphttps://www.pharmaradar360.com/article/set-yourself-up-for-a-strong-2027-2-pharmaceutical-stocks-to-buy-in-september-8cc69ed199f1afbfPharmaRadar360en2026-09-11T09:35:00.000ZSet Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in Septemberhttps://www.pharmaradar360.com/article/head-of-german-venture-fund-sees-big-potential-in-danish-biotech-but-investors-a-cbacdcd980c6a8e4PharmaRadar360en2026-09-11T09:35:00.000ZHead of German venture fund sees big potential in Danish biotech – but investors are lackinghttps://www.pharmaradar360.com/article/are-you-working-with-the-non-clinical-package-for-clinical-trial-applications-se-381cb66138accd14PharmaRadar360en2026-09-11T09:34:00.000ZAre you working with the non-clinical package for clinical trial applications? See Q&A-update!https://www.pharmaradar360.com/article/rewriting-the-rules-of-genetic-medicine-with-trna-therapeutics-beyond-biotech-aee67803a2f832f6PharmaRadar360en2026-09-11T09:33:28.000ZRewriting the rules of genetic medicine with tRNA therapeutics｜Beyond Biotechhttps://www.pharmaradar360.com/article/trial-misses-prompt-shake-up-call-from-major-novartis-stockholder-9b04ea1f348cb183PharmaRadar360en2026-09-11T09:27:43.000ZTrial misses prompt shake-up call from major Novartis stockholderhttps://www.pharmaradar360.com/article/what-regulators-ask-when-ai-touches-a-drug-application-601c189441f030a0PharmaRadar360en2026-09-11T09:27:43.000ZWhat regulators ask when AI touches a drug applicationhttps://www.pharmaradar360.com/article/key-approvals-positive-study-results-and-a-partnership-deal-to-fast-track-new-me-4a3eb1cbd863abcdPharmaRadar360en2026-09-11T09:25:17.000ZKey approvals, positive study results and a partnership deal to fast track new medicationshttps://www.pharmaradar360.com/article/shanghai-henlius-biotech-inc-announces-acceptance-of-new-drug-application-for-12-deaaab0cc42dfe4bPharmaRadar360en2026-09-11T09:20:41.000ZShanghai Henlius Biotech, Inc. Announces Acceptance Of New Drug Application For 120 Mg (1.7 Ml) Per Vial Strength Of Biosimilar Of Denosumab HLX14https://www.pharmaradar360.com/article/meet-the-under-35s-shaping-the-future-of-biotech-0e01cfbafd7d371bPharmaRadar360en2026-09-11T09:00:00.000ZMeet the under-35s shaping the future of biotechhttps://www.pharmaradar360.com/article/aprecia-pharmaceuticals-am-is-an-important-expansion-of-the-pharmaceutical-manuf-fa4992349a80da17PharmaRadar360en2026-09-11T08:51:35.000ZAprecia Pharmaceuticals: 'AM is an important expansion of the pharmaceutical manufacturing toolbox'https://www.pharmaradar360.com/article/veraxa-biotech-vrxa-insider-trading-activity-2026-249623a1453a3bf2PharmaRadar360en2026-09-11T08:46:02.000ZVeraxa Biotech (VRXA) Insider Trading Activity 2026https://www.pharmaradar360.com/article/biotech-for-climate-resilience-fund-31985e360beccdf6PharmaRadar360en2026-09-11T08:43:27.000ZBiotech for Climate Resilience Fundhttps://www.pharmaradar360.com/article/moderna-begins-phase-1-clinical-trial-of-ebola-vaccine-against-strain-behind-drc-0f15edae8af6e558PharmaRadar360en2026-09-11T08:26:58.000ZModerna begins Phase 1 clinical trial of Ebola vaccine against strain behind DRC outbreakhttps://www.pharmaradar360.com/article/fda-advisers-narrowly-vote-to-add-6-peptides-to-a-drug-compounding-list-what-s-n-05eb0af1ede61b6fPharmaRadar360en2026-09-11T08:26:58.000ZFDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?https://www.pharmaradar360.com/article/reporter-s-notebook-k-biopharma-licensing-deals-are-getting-better-not-just-bigg-744ac6deb31a7e39PharmaRadar360en2026-09-11T08:24:18.000Z[Reporter’s Notebook] K-biopharma licensing deals are getting better, not just biggerhttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-13-september-2026-1016782b910b7d0cPharmaRadar360en2026-09-11T08:22:23.000ZWeekly all-cause mortality surveillance: week ending 13 September 2026https://www.pharmaradar360.com/article/astadaily-earns-purity-award-from-clean-label-project-d798f43275060d64PharmaRadar360en2026-09-11T08:20:36.000ZAstadaily earns Purity Award from Clean Label Projecthttps://www.pharmaradar360.com/article/jpmorgan-initiates-dianthus-stock-at-overweight-135-target-76d704bda903e96fPharmaRadar360en2026-09-11T08:12:00.000ZJPMorgan initiates Dianthus stock at Overweight, $135 targethttps://www.pharmaradar360.com/article/biotech-students-must-step-out-of-comfort-zones-embrace-multiple-roles-suchitra-bd66bfb839665905PharmaRadar360en2026-09-11T07:57:14.000ZBiotech students must step out of comfort zones, embrace multiple roles: Suchitra Ellahttps://www.pharmaradar360.com/article/fda-clears-prelude-s-prt13722-phase-1-trial-in-hr-positive-breast-cancer-33a29eff5efb8a93PharmaRadar360en2026-09-11T07:33:49.000ZFDA Clears Prelude’s PRT13722 Phase 1 Trial in HR-Positive Breast Cancerhttps://www.pharmaradar360.com/article/limitless-biotech-coupon-code-pct15-save-15-on-research-peptides-b07e64035e883a26PharmaRadar360en2026-09-11T07:22:22.000ZLimitless Biotech Coupon Code PCT15: Save 15% on Research Peptideshttps://www.pharmaradar360.com/article/kenanga-launches-world-first-hang-seng-biotech-index-structured-warrants-258d523c61bb1937PharmaRadar360en2026-09-11T07:16:49.000ZKenanga launches world first Hang Seng Biotech Index structured warrantshttps://www.pharmaradar360.com/article/marquis-who-s-who-honors-kenneth-hesterman-for-expertise-in-pharmaceutical-accou-4cd9960720360d81PharmaRadar360en2026-09-11T07:02:04.000ZMarquis Who's Who Honors Kenneth Hesterman for Expertise in Pharmaceutical Account Managementhttps://www.pharmaradar360.com/article/pharmaceutical-excipients-market-to-reach-usd-24-88-billion-by-2035-at-8-1-cagr-e55ec71af1e14859PharmaRadar360en2026-09-11T06:57:00.000ZPharmaceutical Excipients Market to reach USD 24.88 Billion by 2035 at 8.1% CAGRhttps://www.pharmaradar360.com/article/novartis-says-closely-watched-cholesterol-study-failed-to-meet-goal-c974947767e107eePharmaRadar360en2026-09-11T06:45:32.000ZNovartis Says Closely Watched Cholesterol Study Failed to Meet Goalhttps://www.pharmaradar360.com/article/phase-3-study-shows-aqivc-superior-to-comparators-in-older-adults-b7ea1dfa91dfde4ePharmaRadar360en2026-09-11T06:38:44.000ZPhase 3 study shows aQIVc superior to comparators in older adultshttps://www.pharmaradar360.com/article/reg-rtw-biotech-opp-additional-investment-in-encoded-therapeutics-06ce266c777880acPharmaRadar360en2026-09-11T06:00:00.000ZREG - RTW Biotech Opp. - Additional investment in Encoded Therapeuticshttps://www.pharmaradar360.com/article/orzeyful-approval-might-change-the-case-for-investing-in-takeda-stock-8b50302be3cb1bfePharmaRadar360en2026-09-11T05:58:28.000ZORZEYFUL Approval Might Change The Case For Investing In Takeda Stockhttps://www.pharmaradar360.com/article/what-strong-biotech-ip-strategies-get-right-and-where-weak-ones-break-down-a2b121fe65165341PharmaRadar360en2026-09-11T05:43:18.000ZWhat Strong Biotech IP Strategies Get Right And Where Weak Ones Break Downhttps://www.pharmaradar360.com/article/comment-climate-change-threatens-pharmaceutical-companies-6987587302b518a2PharmaRadar360en2026-09-11T05:13:58.000ZComment: Climate change threatens pharmaceutical companieshttps://www.pharmaradar360.com/article/former-head-of-takeda-pharmaceutical-dies-at-80-6fc269c48465eb75PharmaRadar360en2026-09-11T05:03:00.000ZFormer head of Takeda Pharmaceutical dies at 80https://www.pharmaradar360.com/article/active-biotech-ab-publ-sto-acti-is-breakeven-near-585e562e6ced9952PharmaRadar360en2026-09-11T04:30:06.000ZActive Biotech AB (publ) (STO:ACTI): Is Breakeven Near?https://www.pharmaradar360.com/article/fda-partially-halts-trials-of-sk-biopharmaceuticals-epilepsy-drug-candidate-e77116af26fe1e1fPharmaRadar360en2026-09-11T04:17:50.000ZFDA partially halts trials of SK Biopharmaceuticals’ epilepsy drug candidatehttps://www.pharmaradar360.com/article/west-pharmaceutical-services-senior-vp-favorite-sells-2-77m-in-stock-9fe9896a7541d2cbPharmaRadar360en2026-09-11T04:16:00.000ZWest Pharmaceutical Services senior VP favorite sells $2.77m in stockhttps://www.pharmaradar360.com/article/jiangsu-handian-biotech-lands-tens-of-millions-of-yuan-in-strategic-round-89239b47de33a798PharmaRadar360en2026-09-11T04:01:52.000ZJiangsu Handian Biotech lands tens of millions of yuan in strategic roundhttps://www.pharmaradar360.com/article/ex-takeda-pharmaceutical-head-hasegawa-dies-at-80-07ac3ad58f8939edPharmaRadar360en2026-09-11T03:54:56.000ZEx-Takeda Pharmaceutical Head Hasegawa Dies at 80https://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-asx-par-draws-final-us-2-million-tranche-as-phase-3-a44324072bfb26c8PharmaRadar360en2026-09-11T03:18:00.000ZParadigm Biopharmaceuticals (ASX:PAR) Draws Final US$2 Million Tranche as Phase 3 Trial Advanceshttps://www.pharmaradar360.com/article/fda-halts-sk-biopharm-s-opcalim-novartis-12-billion-drug-fails-phase-3-0ab09b28ac07fe98PharmaRadar360en2026-09-11T03:09:41.000ZFDA Halts SK Biopharm's OPCALIM; Novartis' $12 Billion Drug Fails Phase 3https://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-secures-additional-funding-for-phase-3-clinical-tria-ddb4fb8de8310392PharmaRadar360en2026-09-11T03:07:34.000ZParadigm Biopharmaceuticals Secures Additional Funding for Phase 3 Clinical Trialhttps://www.pharmaradar360.com/article/laser-therapy-offers-new-hope-for-inoperable-pancreatic-tumors-aa7039f94cc04951PharmaRadar360en2026-09-11T03:01:00.000ZLaser therapy offers new hope for inoperable pancreatic tumorshttps://www.pharmaradar360.com/article/viking-therapeutics-aims-high-at-92-target-but-clinical-risks-remain-cdae87387dc82248PharmaRadar360en2026-09-11T02:54:38.000ZViking Therapeutics Aims High at $92 Target, But Clinical Risks Remainhttps://www.pharmaradar360.com/article/data-aggregation-drives-ai-s-impact-on-clinical-supply-chains-c09c4abbac6eea8fPharmaRadar360en2026-09-11T02:41:32.000ZData Aggregation Drives AI's Impact on Clinical Supply Chainshttps://www.pharmaradar360.com/article/more-than-28-000-bottles-of-blood-pressure-drug-recalled-fda-11bf9d424e5e5c88PharmaRadar360en2026-09-11T02:31:59.000ZMore Than 28,000 Bottles of Blood Pressure Drug Recalled: FDAhttps://www.pharmaradar360.com/article/biotech-stocks-need-a-shot-in-the-arm-after-brutal-july-could-astrazeneca-bristo-0c28c1010a46e800PharmaRadar360en2026-09-11T02:30:30.000ZBiotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure?https://www.pharmaradar360.com/article/agenda-for-november-2026-cancer-treatments-ctac-meeting-3a6d1f5f98e260f8PharmaRadar360en2026-09-11T02:00:00.000ZAgenda for November 2026 Cancer Treatments (CTAC) meetinghttps://www.pharmaradar360.com/article/frazier-life-sciences-adds-1-1b-to-biotech-public-fund-lifting-it-to-2-8b-e142f1ed47f39964PharmaRadar360en2026-09-11T01:48:06.000ZFrazier Life Sciences adds $1.1B to biotech public fund, lifting it to $2.8Bhttps://www.pharmaradar360.com/article/genscript-biotech-to-place-77-1-million-shares-at-hk-30-50-per-share-586a45444917dbb9PharmaRadar360en2026-09-11T01:29:44.000ZGenscript Biotech To Place 77.1 Million Shares At HK$30.50 Per Sharehttps://www.pharmaradar360.com/article/annual-iipa-debate-2026-ku-fda-plan-major-food-safety-awareness-push-in-j-k-415bf82849db4727PharmaRadar360en2026-09-11T01:24:57.000ZAnnual IIPA Debate-2026: KU, FDA plan major food-safety awareness push in J&Khttps://www.pharmaradar360.com/article/is-teva-pharmaceutical-industries-nyse-teva-still-a-bargain-or-fully-priced-22afb570e071b7c5PharmaRadar360en2026-09-11T01:16:33.000ZIs Teva Pharmaceutical Industries (NYSE:TEVA) Still A Bargain Or Fully Priced?https://www.pharmaradar360.com/article/is-teva-pharmaceutical-industries-nyse-teva-still-a-bargain-or-fully-priced-a490fd25a3336a5ePharmaRadar360en2026-09-11T01:15:08.000ZIs Teva Pharmaceutical Industries (NYSE:TEVA) Still A Bargain Or Fully Priced?https://www.pharmaradar360.com/article/exclusive-genencell-treatment-with-elevated-liver-enzymes-approved-for-clinical-775a5811d53df627PharmaRadar360en2026-09-11T01:11:03.000Z[Exclusive] Genencell Treatment With Elevated Liver Enzymes Approved for Clinical Trials Without Hepatotoxicity Indicatorshttps://www.pharmaradar360.com/article/us-fda-pauses-new-enrollment-in-biohaven-s-epilepsy-drug-trials-f4e06e3e7cd27817PharmaRadar360en2026-09-11T01:05:11.000ZUS FDA pauses new enrollment in Biohaven's epilepsy drug trialshttps://www.pharmaradar360.com/article/tukaram-mundhe-s-food-order-for-festivals-what-maharashtra-fda-commissioner-said-3dd813ddcd70dbc5PharmaRadar360en2026-09-11T00:10:17.000ZTukaram Mundhe’s food order for festivals: What Maharashtra FDA Commissioner said about food safety ruleshttps://www.pharmaradar360.com/article/megazonecloud-begins-building-hanmi-pharmaceutical-s-quality-assurance-ai-agent-34906fa2a5c01536PharmaRadar360en2026-09-11T00:06:00.000ZMegazoneCloud Begins Building Hanmi Pharmaceutical's Quality Assurance AI Agent with 'AIR Studio'https://www.pharmaradar360.com/article/gsk-filed-form-6-k-130362fb32f7b414PharmaRadar360en2026-09-11T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-7584d6fa6e4ae920PharmaRadar360en2026-09-11T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-9ef22d0b3e10454aPharmaRadar360en2026-09-11T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-cdd95bf3559e4cecPharmaRadar360en2026-09-11T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-0c0fb15eb6c3b812PharmaRadar360en2026-09-11T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-eaeaad2b1757f369PharmaRadar360en2026-09-11T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-fec20d0ecf6e8a08PharmaRadar360en2026-09-11T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-e3f885ccf75002b9PharmaRadar360en2026-09-11T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-387b96369039a218PharmaRadar360en2026-09-11T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-7f5456fbff2a09dbPharmaRadar360en2026-09-11T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-afe80eb92a8c9c39PharmaRadar360en2026-09-11T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-a6fe3f8b4d203625PharmaRadar360en2026-09-11T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-68ff035afccb0a3ePharmaRadar360en2026-09-11T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-ea300a76aa4bfbd0PharmaRadar360en2026-09-11T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-9844da1238f74937PharmaRadar360en2026-09-11T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/national-heart-lung-and-blood-institute-notice-of-meeting-a3006d086a794e13PharmaRadar360en2026-09-11T00:00:00.000ZNational Heart, Lung, and Blood Institute; Notice of Meetinghttps://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-cardiovascular-mach-212eaf111483ed36PharmaRadar360en2026-09-11T00:00:00.000ZMedical Devices; Cardiovascular Devices; Classification of the Cardiovascular Machine Learning-Based Notification Softwarehttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-577ad723f444fe54PharmaRadar360en2026-09-11T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/emran-mohammad-rn-aprn-cnp-decision-and-order-c222547fc36d6725PharmaRadar360en2026-09-11T00:00:00.000ZEmran Mohammad, RN, APRN, CNP; Decision and Orderhttps://www.pharmaradar360.com/article/joseph-john-stubbers-iii-d-o-decision-and-order-56e3d57bd217be2ePharmaRadar360en2026-09-11T00:00:00.000ZJoseph John Stubbers III, D.O.; Decision and Orderhttps://www.pharmaradar360.com/article/cheryl-white-n-p-decision-and-order-6910fc9ec09361e7PharmaRadar360en2026-09-11T00:00:00.000ZCheryl White, N.P.; Decision and Orderhttps://www.pharmaradar360.com/article/craig-cohen-dpm-decision-and-order-bac086480e607f05PharmaRadar360en2026-09-11T00:00:00.000ZCraig Cohen, DPM; Decision and Orderhttps://www.pharmaradar360.com/article/notice-of-supplemental-funding-appalachian-region-healthcare-support-program-eb7a15e20f6e765dPharmaRadar360en2026-09-11T00:00:00.000ZNotice of Supplemental Funding, Appalachian Region Healthcare Support Programhttps://www.pharmaradar360.com/article/notice-of-supplemental-funding-infant-toddler-court-program-state-awards-556a097130f48a79PharmaRadar360en2026-09-11T00:00:00.000ZNotice of Supplemental Funding, Infant-Toddler Court Program-State Awardshttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-cbd46bd70ec39a02PharmaRadar360en2026-09-11T00:00:00.000ZAgency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Rural Health Network Development Program Performance Improvement and Measurement System, OMB No. 0906-0010-Revisionhttps://www.pharmaradar360.com/article/amending-over-the-counter-monograph-m020-sunscreen-drug-products-for-over-the-co-bf1f21ba8881a138PharmaRadar360en2026-09-11T00:00:00.000ZAmending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information; Aminobenzoic Acid (PABA) and Trolamine Salicylatehttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-med-93720515e76d644fPharmaRadar360en2026-09-11T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Medical Device Trackinghttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-c7cf00b962ad7623PharmaRadar360en2026-09-11T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Generic Clearance for Qualitative Data To Support Social and Behavioral Research for Food, Dietary Supplements, Cosmetics, and Animal Food and Feedhttps://www.pharmaradar360.com/article/notice-of-supplemental-funding-rural-hospital-stabilization-pilot-program-f42ef2358c137743PharmaRadar360en2026-09-11T00:00:00.000ZNotice of Supplemental Funding, Rural Hospital Stabilization Pilot Programhttps://www.pharmaradar360.com/article/national-institute-on-aging-amended-notice-of-meeting-05a388dc6e88ab98PharmaRadar360en2026-09-11T00:00:00.000ZNational Institute on Aging; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/national-institute-of-diabetes-and-digestive-and-kidney-diseases-amended-notice-943f33d3924a19c8PharmaRadar360en2026-09-11T00:00:00.000ZNational Institute of Diabetes and Digestive and Kidney Diseases; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-e4c7ec9101c7b4edPharmaRadar360en2026-09-11T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/study-shows-benefits-of-coffee-for-liver-health-db0567cadb2381baPharmaRadar360en2026-09-11T00:00:00.000ZStudy Shows Benefits of Coffee for Liver Healthhttps://www.pharmaradar360.com/article/the-race-for-the-next-big-weight-loss-drug-is-on-and-china-wants-in-4ca0025474e6d592PharmaRadar360en2026-09-11T00:00:00.000ZThe Race for the Next Big Weight-Loss Drug Is On—and China Wants Inhttps://www.pharmaradar360.com/article/what-services-do-people-seek-when-they-visit-a-community-pharmacy-care-clinic-d0b530ddc5e44386PharmaRadar360en2026-09-11T00:00:00.000ZWhat services do people seek when they visit a community pharmacy care clinic?https://www.pharmaradar360.com/article/managing-patients-with-heart-failure-a-contemporary-practice-tool-for-pharmacist-7c408d6b46d4237cPharmaRadar360en2026-09-11T00:00:00.000ZManaging patients with heart failure: A contemporary practice tool for pharmacistshttps://www.pharmaradar360.com/article/medication-safety-in-indigenous-communities-challenges-and-interventions-1bf49ca019f7d0e2PharmaRadar360en2026-09-11T00:00:00.000ZMedication safety in Indigenous communities: Challenges and interventionshttps://www.pharmaradar360.com/article/ten-year-analysis-of-publications-by-quebec-hospital-pharmacists-8f6c95173b5e694fPharmaRadar360en2026-09-11T00:00:00.000ZTen-year analysis of publications by Quebec hospital pharmacistshttps://www.pharmaradar360.com/article/drug-related-problems-in-older-adults-with-mild-cognitive-impairment-or-dementia-96f624acc8f4f4a9PharmaRadar360en2026-09-11T00:00:00.000ZDrug-related problems in older adults with mild cognitive impairment or dementia: A cross-sectional comparison of 2 different instrumentshttps://www.pharmaradar360.com/article/management-of-a-patient-with-a-ticagrelor-rosuvastatin-interaction-an-algorithm-9d231ffd5b5bc159PharmaRadar360en2026-09-11T00:00:00.000ZManagement of a patient with a ticagrelor–rosuvastatin interaction: An algorithm-based tool kit for pharmacistshttps://www.pharmaradar360.com/article/a-call-for-the-generalist-pharmacist-bdb545612f6c918fPharmaRadar360en2026-09-11T00:00:00.000ZA call for the generalist pharmacisthttps://www.pharmaradar360.com/article/late-onset-multiple-acyl-coa-dehydrogenase-deficiency-madd-glutaric-acidemia-typ-26ad462a8ff18b6ePharmaRadar360en2026-09-11T00:00:00.000ZLate-Onset Multiple Acyl-CoA Dehydrogenase Deficiency (MADD / Glutaric Acidemia Type IIC) Presenting as Chronic Sensory Ataxic Ganglionopathy, Bilateral Sensorineural Hearing Loss, and Vocal Cord Dysfunction Associated with a Novel ETFDH Varianthttps://www.pharmaradar360.com/article/benchmarking-drug-library-compliance-and-alert-rates-in-smart-infusion-pumps-a-m-cc042761c50bfb5ePharmaRadar360en2026-09-11T00:00:00.000ZBenchmarking Drug Library Compliance and Alert Rates in Smart Infusion Pumps: A Multicenter Retrospective Studyhttps://www.pharmaradar360.com/article/successful-management-of-generalized-drug-influenced-gingival-enlargement-a-clin-a0dff0eeba02fdcaPharmaRadar360en2026-09-11T00:00:00.000ZSuccessful Management of Generalized Drug-Influenced Gingival Enlargement: A Clinical Case Reporthttps://www.pharmaradar360.com/article/clinical-phenotypes-and-factors-associated-with-systemic-involvement-in-pediatri-bb23bbedc93d5e22PharmaRadar360en2026-09-11T00:00:00.000ZClinical Phenotypes and Factors Associated with Systemic Involvement in Pediatric IgA Vasculitis: A Single-Center Study from Southeastern Türkiyehttps://www.pharmaradar360.com/article/the-ictal-interictal-continuum-a-comprehensive-review-for-the-clinical-epileptol-1d28a0773cd7a283PharmaRadar360en2026-09-11T00:00:00.000ZThe Ictal-Interictal Continuum: A Comprehensive Review for the Clinical Epileptologisthttps://www.pharmaradar360.com/article/the-impact-of-medical-procedure-in-needle-stick-injuries-among-healthcare-practi-a625c88de71da316PharmaRadar360en2026-09-11T00:00:00.000ZThe Impact of Medical Procedure in Needle Stick Injuries Among Healthcare Practitioners in Tertiary Hospitals, Rivers Statehttps://www.pharmaradar360.com/article/knowledge-attitudes-and-practices-regarding-hypertension-prevention-among-medica-95ce3ccfb7d13a35PharmaRadar360en2026-09-11T00:00:00.000ZKnowledge, Attitudes, and Practices Regarding Hypertension Prevention Among Medical Students: A Cross-Sectional Study at Agostinho Neto Universityhttps://www.pharmaradar360.com/article/acupuncture-care-for-a-patient-with-tennis-elbow-lateral-elbow-tendinopathy-a-ca-55448e3e6a6b64cePharmaRadar360en2026-09-11T00:00:00.000ZAcupuncture Care For A Patient With Tennis Elbow (Lateral Elbow Tendinopathy): A Case Reporthttps://www.pharmaradar360.com/article/i-ll-see-it-when-i-believe-it-73965d6ba86bbf24PharmaRadar360en2026-09-11T00:00:00.000ZI'll See It When I Believe Ithttps://www.pharmaradar360.com/article/the-practitioner-s-guide-to-ericksonian-choice-architecture-7ba5e46554ae733ePharmaRadar360en2026-09-11T00:00:00.000ZThe Practitioner's Guide to Ericksonian Choice Architecturehttps://www.pharmaradar360.com/article/effectiveness-of-olfactory-training-and-topical-corticosteroids-for-persistent-p-284ef17782a9bce4PharmaRadar360en2026-09-11T00:00:00.000ZEffectiveness of olfactory training and topical corticosteroids for persistent post-COVID-19 anosmia and hyposmia: A prospective randomized controlled trialhttps://www.pharmaradar360.com/article/future-directions-b7312a04957ae1cbPharmaRadar360en2026-09-11T00:00:00.000ZFuture Directionshttps://www.pharmaradar360.com/article/teaching-the-invisible-a-game-based-simulation-for-learning-health-care-economic-7ea5cdfe5504fe20PharmaRadar360en2026-09-11T00:00:00.000ZTeaching the Invisible: A Game-Based Simulation for Learning Health Care Economics in Clinical Nurse Leader Educationhttps://www.pharmaradar360.com/article/pre-diagnostic-identification-of-cholestatic-liver-diseases-using-integrated-cli-89d880bf052825c6PharmaRadar360en2026-09-11T00:00:00.000ZPre-diagnostic identification of cholestatic liver diseases using integrated clinical and environmental data frameworkhttps://www.pharmaradar360.com/article/chemical-fingerprinting-and-simultaneous-determination-of-main-compounds-combine-c618963982a18705PharmaRadar360en2026-09-11T00:00:00.000ZChemical fingerprinting and simultaneous determination of main compounds combined with multivariate analysis of the Syringa pubescens Turcz. leaves from different originshttps://www.pharmaradar360.com/article/localization-of-advanced-drug-delivery-manufacturing-in-saudi-arabia-through-tec-a5d3d641a0ae9b7dPharmaRadar360en2026-09-11T00:00:00.000ZLocalization of Advanced Drug-Delivery Manufacturing in Saudi Arabia Through Technology Transfer and Pharmaceutical Process Scale-Uphttps://www.pharmaradar360.com/article/fused-spinopelvic-angle-in-adult-spinal-deformity-with-pure-sagittal-malalignmen-a50ebbefa1722eb4PharmaRadar360en2026-09-11T00:00:00.000ZFused Spinopelvic Angle in Adult Spinal Deformity with Pure Sagittal Malalignment: A Postoperative Threshold Associated with Proximal Junctional Kyphosishttps://www.pharmaradar360.com/article/predictive-analysis-of-social-determinants-of-health-in-posterior-cervical-spine-990d69caca0e348fPharmaRadar360en2026-09-11T00:00:00.000ZPredictive Analysis of Social Determinants of Health in Posterior Cervical Spine Surgeryhttps://www.pharmaradar360.com/article/association-between-physical-therapy-and-mortality-in-older-patients-with-heart-9c687d7a8b736236PharmaRadar360en2026-09-11T00:00:00.000ZAssociation Between Physical Therapy and Mortality in Older Patients with Heart Failure and Chronic Kidney Diseasehttps://www.pharmaradar360.com/article/hydrus-microstent-combined-with-cataract-surgery-in-pseudoexfoliation-glaucoma-v-da281f09101151eaPharmaRadar360en2026-09-11T00:00:00.000ZHydrus® Microstent Combined with Cataract Surgery in Pseudoexfoliation Glaucoma Versus Primary Open Angle Glaucomahttps://www.pharmaradar360.com/article/functional-status-and-postoperative-outcomes-after-left-pancreatectomy-for-pancr-ece63d7def3a3618PharmaRadar360en2026-09-11T00:00:00.000ZFunctional Status and Postoperative Outcomes After Left Pancreatectomy for Pancreatic Neuroendocrine Tumors: An Exploratory Analysis from the Prospective SPANDISPAN Studyhttps://www.pharmaradar360.com/article/diagnostic-approach-and-therapeutic-management-of-spontaneous-esophageal-perfora-729725021ca6e7c5PharmaRadar360en2026-09-11T00:00:00.000ZDiagnostic Approach and Therapeutic Management of Spontaneous Esophageal Perforation (Boerhaave’s Syndrome): A Systematic Review and Individual Patient-Level Pooled Analysishttps://www.pharmaradar360.com/article/the-implementation-and-clinical-validation-of-a-whole-genome-sequencing-non-inva-5efd029892d9731cPharmaRadar360en2026-09-11T00:00:00.000ZThe Implementation and Clinical Validation of a Whole-Genome Sequencing Non-Invasive Prenatal Test in a High-Complexity Clinical Laboratory: A Retrospective Analysis of 11,235 Pregnancieshttps://www.pharmaradar360.com/article/risk-stratification-of-acute-symptomatic-anterior-circulation-intracranial-ather-060335b18fc361eePharmaRadar360en2026-09-11T00:00:00.000ZRisk stratification of acute symptomatic anterior circulation intracranial atherosclerotic stenosis using an ABCD3-I-informed clinical-imaging score: an exploratory studyhttps://www.pharmaradar360.com/article/a-clinical-study-of-simotang-oral-liquid-combined-with-shenque-acupoint-applicat-d4b5d7677424f285PharmaRadar360en2026-09-11T00:00:00.000ZA clinical study of Simotang oral liquid combined with Shenque acupoint application for abdominal distension after cesarean sectionhttps://www.pharmaradar360.com/article/fusion-level-selection-in-posterior-hemivertebra-resection-for-congenital-scolio-4356d58d5169b806PharmaRadar360en2026-09-11T00:00:00.000ZFusion level selection in posterior hemivertebra resection for congenital scoliosis: clinical effect size driven feature selection and multi-criteria optimization decision modelhttps://www.pharmaradar360.com/article/rethinking-ai-in-clinical-decision-support-a-framework-for-reciprocal-human-ai-i-1420c6c6866df483PharmaRadar360en2026-09-11T00:00:00.000ZRethinking AI in clinical decision support: a framework for reciprocal human-AI interactionhttps://www.pharmaradar360.com/article/clinical-efficacy-of-radix-arnebiae-oil-in-patients-undergoing-incision-and-drai-58f0e461772494f1PharmaRadar360en2026-09-11T00:00:00.000ZClinical efficacy of Radix Arnebiae oil in patients undergoing incision and drainage of perianal abscess and its effects on pyroptosishttps://www.pharmaradar360.com/article/fetal-behavior-as-a-window-to-later-gross-motor-function-a-10-year-follow-up-of-c8f670e65987c96ePharmaRadar360en2026-09-11T00:00:00.000ZFetal behavior as a window to later gross motor function: a 10-year follow-up of children prenatally exposed to gestational diabetes mellitushttps://www.pharmaradar360.com/article/clinical-and-laboratory-criteria-for-a-differentiated-approach-to-the-management-d489377a752957d5PharmaRadar360en2026-09-11T00:00:00.000ZClinical and laboratory criteria for a differentiated approach to the management of children harboring opportunistic protozoa: a retrospective analysishttps://www.pharmaradar360.com/article/efficacy-of-dapagliflozin-in-the-treatment-of-patients-with-signs-of-cardio-rena-d4a6bb4196d21d84PharmaRadar360en2026-09-11T00:00:00.000ZEFFICACY OF DAPAGLIFLOZIN IN THE TREATMENT OF PATIENTS WITH SIGNS OF CARDIO-RENAL-METABOLIC SYNDROMEhttps://www.pharmaradar360.com/article/clinical-rationale-for-individualizing-secondary-prevention-in-patients-with-ath-c7a775dd082043baPharmaRadar360en2026-09-11T00:00:00.000ZCLINICAL RATIONALE FOR INDIVIDUALIZING SECONDARY PREVENTION IN PATIENTS WITH ATHEROTHROMBOTIC STROKE BASED ON PLATELET AGGREGATION MONITORINGhttps://www.pharmaradar360.com/article/edukasi-tentang-hoaks-obat-dan-kesehatan-di-media-sosial-dengan-bijak-berselanca-5fa5e8f4010bbf01PharmaRadar360en2026-09-11T00:00:00.000ZEdukasi tentang Hoaks Obat dan Kesehatan di Media Sosial dengan Bijak Berselancar Bijak Berobathttps://www.pharmaradar360.com/article/clinical-characteristics-and-surgical-outcomes-of-split-cord-malformations-a-ret-a259bf8535951c1fPharmaRadar360en2026-09-11T00:00:00.000ZClinical characteristics and surgical outcomes of split cord malformations: A retrospective analysishttps://www.pharmaradar360.com/article/evaluating-prevent-for-cardiokidney-outcomes-in-ckd-076f0a826668143cPharmaRadar360en2026-09-11T00:00:00.000ZEvaluating PREVENT for Cardiokidney Outcomes in CKDhttps://www.pharmaradar360.com/article/executive-functions-and-conceptual-models-a-first-look-at-a-complex-topic-commen-237f2f36d13ca767PharmaRadar360en2026-09-11T00:00:00.000ZExecutive Functions and Conceptual Models: A First Look at a Complex Topic: Commentaryhttps://www.pharmaradar360.com/article/integrating-computed-tomography-and-magnetic-resonance-imaging-education-into-a-916bc317b1b11c9cPharmaRadar360en2026-09-11T00:00:00.000ZIntegrating Computed Tomography and Magnetic Resonance Imaging education into a clinical clerkship through specialist-led, case-based learning: a mixed-methods evaluationhttps://www.pharmaradar360.com/article/preparation-and-characterization-of-chitosan-co-acrylamide-hydrogels-for-control-6272337bb2bce876PharmaRadar360en2026-09-11T00:00:00.000ZPreparation and characterization of chitosan-co-acrylamide hydrogels for controlled drug deliveryhttps://www.pharmaradar360.com/article/enhancing-guideline-directed-medical-therapy-at-discharge-through-collaborative-61c425f8c65f8565PharmaRadar360en2026-09-11T00:00:00.000ZEnhancing Guideline-Directed Medical Therapy at Discharge Through Collaborative Care: Evidence from the TIME-HF Cluster Randomized Controlled Trialhttps://www.pharmaradar360.com/article/clinical-relevance-of-accuracy-in-in-house-3d-printing-in-craniomaxillofacial-su-5d29ff74d526eef8PharmaRadar360en2026-09-11T00:00:00.000ZClinical relevance of accuracy in in-house 3D printing in craniomaxillofacial surgery: a comparative study of FFF, SLA, and MJ technologieshttps://www.pharmaradar360.com/article/effect-of-theory-based-health-education-intervention-in-improving-exclusive-brea-3c22484e4d298979PharmaRadar360en2026-09-11T00:00:00.000ZEffect of theory-based health education intervention in improving exclusive breastfeeding intention among working mothers: a study protocol for a cluster randomised controlled trialhttps://www.pharmaradar360.com/article/evaluation-of-the-feasibility-usability-and-preliminary-effects-of-an-mhealth-in-61c938230b152285PharmaRadar360en2026-09-11T00:00:00.000ZEvaluation of the feasibility, usability, and preliminary effects of an mHealth intervention complementary to usual care in individuals with heart failure: protocol for a pilot randomized clinical trialhttps://www.pharmaradar360.com/article/clinical-outcomes-of-cavaterm-thermal-balloon-endometrial-ablation-in-women-with-9a5696678c3b99a8PharmaRadar360en2026-09-11T00:00:00.000ZClinical outcomes of cavaterm thermal balloon endometrial ablation in women with refractory abnormal uterine bleeding: a multicenter retrospective cohort studyhttps://www.pharmaradar360.com/article/alveolar-ridge-preservation-using-advanced-platelet-rich-fibrin-versus-concentra-642458687bb7b17cPharmaRadar360en2026-09-11T00:00:00.000ZAlveolar ridge preservation using advanced platelet-rich fibrin versus concentrated growth factors: a randomized, controlled trialhttps://www.pharmaradar360.com/article/evaluating-the-therapeutic-efficacy-of-a-modified-ketogenic-diet-in-children-wit-7bdc14cebb6eaee3PharmaRadar360en2026-09-11T00:00:00.000ZEvaluating the therapeutic efficacy of a modified ketogenic diet in children with autism spectrum disorder: a randomized controlled trialhttps://www.pharmaradar360.com/article/effect-of-low-dose-esketamine-on-quality-of-recovery-after-gynecologic-laparosco-9565882e22d28941PharmaRadar360en2026-09-11T00:00:00.000ZEffect of low-dose esketamine on quality of recovery after gynecologic laparoscopic surgery: a randomized controlled trialhttps://www.pharmaradar360.com/article/salivary-lysozymes-anti-inflammatory-cardiac-medications-and-cardiovascular-mort-595fc7d8250f6e70PharmaRadar360en2026-09-11T00:00:00.000ZSalivary Lysozymes, Anti-inflammatory Cardiac Medications, and Cardiovascular Mortalityhttps://www.pharmaradar360.com/article/the-association-between-hormonal-contraceptives-and-lower-extremity-injuries-in-7f2bf0b2935043e0PharmaRadar360en2026-09-11T00:00:00.000ZThe Association Between Hormonal Contraceptives and Lower Extremity Injuries in Female Athletes With Sports-Related Clinical Encountershttps://www.pharmaradar360.com/article/uncertainty-and-novel-clinical-trial-designs-in-oncology-when-should-equipoise-m-9d09e54cf8511c76PharmaRadar360en2026-09-11T00:00:00.000ZUncertainty and novel clinical trial designs in oncology – when should equipoise matter?https://www.pharmaradar360.com/article/from-discrimination-to-decision-external-validation-and-clinical-utility-of-a-di-fc08c4cab53491f2PharmaRadar360en2026-09-11T00:00:00.000ZFrom Discrimination to Decision: External Validation and Clinical Utility of a Diabetic Foot Ulcer Prediction Modelhttps://www.pharmaradar360.com/article/oculomics-and-cardiovascular-disease-from-enthusiasm-to-clinical-reality-845c121fddcc7236PharmaRadar360en2026-09-11T00:00:00.000ZOculomics and cardiovascular disease: From enthusiasm to clinical realityhttps://www.pharmaradar360.com/article/mitral-regurgitation-and-severe-aortic-stenosis-clinical-characteristics-prognos-56a6b86519668248PharmaRadar360en2026-09-11T00:00:00.000ZMitral Regurgitation and Severe Aortic Stenosis: Clinical Characteristics, Prognostic Impact, and Response to TAVR: Insights From Egnite Datahttps://www.pharmaradar360.com/article/safety-and-efficacy-of-intratumoral-medi1191-an-il12-mrna-lipid-nanoparticle-plu-9feec652d62b5a63PharmaRadar360en2026-09-11T00:00:00.000ZSafety and Efficacy of Intratumoral MEDI1191, an IL12 mRNA Lipid Nanoparticle, plus Intravenous Durvalumab in Patients with Advanced Solid Tumors: A First-in-Human Studyhttps://www.pharmaradar360.com/article/spatiotemporal-mapping-of-tertiary-lymphoid-structure-heterogeneity-shapes-immun-b878c7a6750a845ePharmaRadar360en2026-09-11T00:00:00.000ZSpatiotemporal mapping of tertiary lymphoid structure heterogeneity shapes immune niches and clinical outcomes in intrahepatic cholangiocarcinomahttps://www.pharmaradar360.com/article/differentiation-between-bipolar-versus-unipolar-depression-by-ai-based-multimoda-10811a17d96af235PharmaRadar360en2026-09-11T00:00:00.000ZDifferentiation between bipolar versus unipolar depression by AI‐based multimodal behavioral analysishttps://www.pharmaradar360.com/article/lignan-rich-norway-spruce-i-picea-abies-i-resin-extract-exhibits-anti-inflammato-bbbefd8591a7808aPharmaRadar360en2026-09-11T00:00:00.000ZLignan‐rich Norway spruce ( <i>Picea abies</i> ) resin extract exhibits anti‐inflammatory, skin‐regenerative and anti‐acne effects: In vitro, in silico, biocompatibility and exploratory clinical findingshttps://www.pharmaradar360.com/article/alcohol-and-other-drug-policies-for-health-care-workplaces-evaluation-of-the-con-e99cec33373f8f7bPharmaRadar360en2026-09-11T00:00:00.000ZAlcohol and other drug policies for health care workplaces: evaluation of the content, quality and implementabilityhttps://www.pharmaradar360.com/article/integrating-public-health-advertising-and-the-health-belief-model-to-predict-dia-a0939aee5e67c757PharmaRadar360en2026-09-11T00:00:00.000ZIntegrating public health advertising and the health belief model to predict diabetes prevention intention: evidence from Indonesian young generationshttps://www.pharmaradar360.com/article/interesting-hurdles-in-the-solution-of-pharmaceutical-crystal-structures-using-p-3e514e35adab43a8PharmaRadar360en2026-09-11T00:00:00.000ZInteresting hurdles in the solution of pharmaceutical crystal structures using powder diffraction datahttps://www.pharmaradar360.com/article/anterior-palpability-and-proptosis-as-clinical-predictors-of-ptosis-in-lacrimal-450fcdb8e69e20a6PharmaRadar360en2026-09-11T00:00:00.000ZAnterior Palpability and Proptosis as Clinical Predictors of Ptosis in Lacrimal Gland Tumorshttps://www.pharmaradar360.com/article/what-factors-are-associated-with-shoulder-joint-pain-in-male-swimmers-including-2d4ac870140b4056PharmaRadar360en2026-09-11T00:00:00.000ZWhat Factors Are Associated With Shoulder Joint Pain in Male Swimmers? Including Thoracic Kyphosis Anglehttps://www.pharmaradar360.com/article/value-based-healthcare-scaling-value-based-care-through-surgeon-leadership-452cfb461f6acbc0PharmaRadar360en2026-09-11T00:00:00.000ZValue-based Healthcare: Scaling Value-Based Care Through Surgeon Leadershiphttps://www.pharmaradar360.com/article/pro-ctcae-in-oncology-drug-evaluation-cross-agency-review-of-regulatory-and-heal-e2676d3716a504ebPharmaRadar360en2026-09-11T00:00:00.000ZPRO‑CTCAE in Oncology Drug Evaluation: Cross-Agency Review of Regulatory and Health Technology Assessment Decision-Making in the United States and Europehttps://www.pharmaradar360.com/article/strengthening-the-pre-hospital-chain-of-survival-for-out-of-hospital-cardiac-arr-95603fb884f8a5caPharmaRadar360en2026-09-11T00:00:00.000ZStrengthening the Pre-Hospital Chain of Survival for Out-of-Hospital Cardiac Arresthttps://www.pharmaradar360.com/article/optimized-dosing-of-momelotinib-in-myelofibrosis-through-quantitative-medicine-a-82759c408af8a2d1PharmaRadar360en2026-09-11T00:00:00.000ZOptimized dosing of momelotinib in myelofibrosis through quantitative medicine: a clinical commentaryhttps://www.pharmaradar360.com/article/implementing-structured-and-collaborative-clinical-planning-for-comprehensive-hi-2ee6f77428200007PharmaRadar360en2026-09-11T00:00:00.000ZImplementing structured and collaborative clinical planning for Comprehensive, High-Dose Aphasia Treatment (CHAT): a pilot implementation-feasibility studyhttps://www.pharmaradar360.com/article/from-daffodils-to-drug-leads-amaryllidaceae-alkaloids-target-protein-translation-d152f81dc448462fPharmaRadar360en2026-09-11T00:00:00.000ZFrom Daffodils to Drug Leads: Amaryllidaceae Alkaloids Target Protein Translation in Chronic Lymphocytic Leukemia to Induce Selective Apoptosishttps://www.pharmaradar360.com/article/maladaptive-movement-in-eating-disorders-clinical-correlates-and-cross-cultural-88f05d3f85a94292PharmaRadar360en2026-09-11T00:00:00.000ZMaladaptive movement in eating disorders: clinical correlates and cross-cultural adaptation of the Czech exercise and eating disorders questionnairehttps://www.pharmaradar360.com/article/gut-microecology-and-cardiovascular-disease-core-pathogenic-mechanisms-and-clini-3c2babc6119fff71PharmaRadar360en2026-09-11T00:00:00.000ZGut microecology and cardiovascular disease: core pathogenic mechanisms and clinical intervention strategieshttps://www.pharmaradar360.com/article/burnout-factors-for-pediatric-psychologists-across-career-stages-70a346964a211cd9PharmaRadar360en2026-09-11T00:00:00.000ZBurnout Factors for Pediatric Psychologists Across Career Stageshttps://www.pharmaradar360.com/article/oligoclonal-band-count-as-a-marker-of-mri-lesion-burden-and-clinical-profile-in-750eee9cb00a292ePharmaRadar360en2026-09-11T00:00:00.000ZOligoclonal band count as a marker of MRI lesion burden and clinical profile in newly diagnosed multiple sclerosishttps://www.pharmaradar360.com/article/clinical-and-mri-features-associated-with-remission-following-biological-therapy-0d857f7086779929PharmaRadar360en2026-09-11T00:00:00.000ZClinical and MRI features associated with remission following biological therapy in axial spondyloarthritishttps://www.pharmaradar360.com/article/repeated-perioperative-hypersensitivity-reactions-and-positive-challenge-testing-a6d40ff19fd054a0PharmaRadar360en2026-09-11T00:00:00.000ZRepeated perioperative hypersensitivity reactions and positive challenge testing strongly suggest sevoflurane hypersensitivity: a clinical report with supportive basophil activation testinghttps://www.pharmaradar360.com/article/safety-of-nonsteroidal-anti-inflammatory-drug-use-in-traumatic-brain-injury-579799c9f9af014aPharmaRadar360en2026-09-11T00:00:00.000ZSafety of Nonsteroidal Anti‐Inflammatory Drug Use in Traumatic Brain Injuryhttps://www.pharmaradar360.com/article/pharmacokinetics-of-loading-dose-vigabatrin-administered-via-enteral-tube-in-par-90af192c98b082d8PharmaRadar360en2026-09-11T00:00:00.000ZPharmacokinetics of Loading Dose Vigabatrin Administered via Enteral Tube in Participants With Post‐Anoxic Status Epilepticushttps://www.pharmaradar360.com/article/responsible-implementation-of-ehr-based-clinical-prediction-models-beyond-perfor-eecda7cc2a55f5b8PharmaRadar360en2026-09-11T00:00:00.000ZResponsible Implementation of EHR-Based Clinical Prediction Models—Beyond Performancehttps://www.pharmaradar360.com/article/nct07816575-comparative-efficacy-of-alpha-hydroxy-acids-with-and-without-nanocar-d7ef75d6761b1a5dPharmaRadar360en2026-09-11T00:00:00.000ZNCT07816575: Comparative Efficacy of Alpha Hydroxy Acids With and Without Nanocarriers Versus Calcipotriol Plus Betamethasone in Treatment of Plaque Psoriasishttps://www.pharmaradar360.com/article/nct07816510-combination-of-oral-antifungal-treatment-for-refractory-dermatophyto-702068d4be42e1c4PharmaRadar360en2026-09-11T00:00:00.000ZNCT07816510: Combination of Oral Antifungal Treatment for Refractory Dermatophytosishttps://www.pharmaradar360.com/article/nct07816328-investigation-of-a-remibrutinib-and-omalizumab-based-treatment-algor-03dcb9b7e3a5e14fPharmaRadar360en2026-09-11T00:00:00.000ZNCT07816328: Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weekshttps://www.pharmaradar360.com/article/nct07815626-phase-3-study-to-evaluate-the-efficacy-and-safety-of-human-growth-ho-6269ee1ed4d7a47cPharmaRadar360en2026-09-11T00:00:00.000ZNCT07815626: Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Staturehttps://www.pharmaradar360.com/article/nct07815301-gradual-tapering-or-discontinuation-of-beta-blockers-after-stabiliza-7fc2e5dc6cbb93d7PharmaRadar360en2026-09-11T00:00:00.000ZNCT07815301: Gradual Tapering or Discontinuation of Beta-Blockers After Stabilization With Mavacamten Therapyhttps://www.pharmaradar360.com/article/nct07814365-pbi-for-low-risk-breast-cancer-a312bf3a7dc39711PharmaRadar360en2026-09-11T00:00:00.000ZNCT07814365: PBI for Low-risk Breast Cancerhttps://www.pharmaradar360.com/article/nct07813949-evaluation-of-clinical-performance-shade-matching-and-patient-satisf-7c074338dfdf4687PharmaRadar360en2026-09-11T00:00:00.000ZNCT07813949: Evaluation of Clinical Performance, Shade Matching, and Patient Satisfaction of Different Resin Composite Layering Techniques Using 3D Printed Casthttps://www.pharmaradar360.com/article/nct07714538-breath-research-narrow-validation-for-gastrointestinal-cancer-detect-8b45a742a232789ePharmaRadar360en2026-09-11T00:00:00.000ZNCT07714538: Breath Research Narrow Validation for Gastrointestinal Cancer Detectionhttps://www.pharmaradar360.com/article/nct07597746-effects-of-a-combined-repetitive-transcranial-magnetic-stimulation-a-8effc8546335d7adPharmaRadar360en2026-09-11T00:00:00.000ZNCT07597746: "Effects of a Combined Repetitive Transcranial Magnetic Stimulation and Physical Therapy Protocol on Motor Function, Balance, and Quality of Life in Chronic Post-Stroke Hemiplegia: A Case Series"https://www.pharmaradar360.com/article/nct07597161-trial-of-device-that-is-not-approved-or-cleared-by-the-u-s-fda-38094db28f64d38dPharmaRadar360en2026-09-11T00:00:00.000ZNCT07597161: [Trial of device that is not approved or cleared by the U.S. FDA]https://www.pharmaradar360.com/article/nct07593079-prostate-specific-membrane-antigen-psma-imaging-for-detection-of-res-b3e776fd82076549PharmaRadar360en2026-09-11T00:00:00.000ZNCT07593079: Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancerhttps://www.pharmaradar360.com/article/nct07575685-enhancing-cancer-care-restoreme-app-for-personalized-nutrition-and-a-35ec302ac93c9811PharmaRadar360en2026-09-11T00:00:00.000ZNCT07575685: Enhancing Cancer Care: RestoreMe App for Personalized Nutrition and Activity in Cancer Patientshttps://www.pharmaradar360.com/article/nct07566156-enfortumab-vedotin-in-combination-with-pembrolizumab-vs-concurrent-c-5e6eb7a3af17cfa1PharmaRadar360en2026-09-11T00:00:00.000ZNCT07566156: Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)https://www.pharmaradar360.com/article/nct07557420-efficacy-safety-pharmacokinetics-pharmacodynamics-and-immunogenicity-d9d2b2f8a4ba8e14PharmaRadar360en2026-09-11T00:00:00.000ZNCT07557420: Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)https://www.pharmaradar360.com/article/nct07489378-nci-childhood-cancer-data-initiative-ccdi-led-pediatric-adolescent-a-c53e59732f23426fPharmaRadar360en2026-09-11T00:00:00.000ZNCT07489378: NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumorshttps://www.pharmaradar360.com/article/nct07416786-validation-of-nad-measurements-for-human-clinical-studies-38d39bd6fb10bbc7PharmaRadar360en2026-09-11T00:00:00.000ZNCT07416786: Validation of NAD+ Measurements for Human Clinical Studieshttps://www.pharmaradar360.com/article/nct07391774-testing-whether-hormone-therapy-with-ribociclib-is-as-effective-as-c-950c4ddcb9c97097PharmaRadar360en2026-09-11T00:00:00.000ZNCT07391774: Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trialhttps://www.pharmaradar360.com/article/nct07388537-evaluation-of-the-clinical-spectrum-of-diabetes-and-obesity-in-youth-3033397525ec41f9PharmaRadar360en2026-09-11T00:00:00.000ZNCT07388537: Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adultshttps://www.pharmaradar360.com/article/nct07370974-effect-of-clinical-hypnosis-in-preoperative-anxiety-among-patients-u-4cedb6dad168e6e8PharmaRadar360en2026-09-11T00:00:00.000ZNCT07370974: Effect of Clinical Hypnosis in Preoperative Anxiety Among Patients Undergoing an Abdominal Surgery.https://www.pharmaradar360.com/article/nct07278739-testing-an-educational-program-to-improve-goals-of-care-conversation-4133918c2dd23ca2PharmaRadar360en2026-09-11T00:00:00.000ZNCT07278739: Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teamshttps://www.pharmaradar360.com/article/nct07226349-a-study-of-bg-75098-alone-and-in-combination-with-other-agents-in-ad-60a0ce7404bbdbf3PharmaRadar360en2026-09-11T00:00:00.000ZNCT07226349: A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumorshttps://www.pharmaradar360.com/article/nct07103109-impact-of-proximal-motor-control-exercise-on-scapular-muscles-activa-602738f19bfdff82PharmaRadar360en2026-09-11T00:00:00.000ZNCT07103109: Impact of Proximal Motor Control Exercise on Scapular Muscles Activation Pattern in Breast Cancer Survivors Following Mastectomyhttps://www.pharmaradar360.com/article/nct07091149-digital-cognitive-behavioral-treatment-of-insomnia-in-youth-an-rct-e-3868d1851c216b7bPharmaRadar360en2026-09-11T00:00:00.000ZNCT07091149: Digital Cognitive Behavioral Treatment of Insomnia in Youth: An RCT Examining Feasibility, Acceptability, and Efficacy of NiteCAPP Jrhttps://www.pharmaradar360.com/article/nct06921850-a-study-to-assess-the-pharmacokinetics-and-safety-of-bimekizumab-in-05eaad6aa11825f1PharmaRadar360en2026-09-11T00:00:00.000ZNCT06921850: A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativahttps://www.pharmaradar360.com/article/nct06920511-cognitive-rehabilitation-with-virtual-reality-in-parkinson-disease-93602a996fb80ba0PharmaRadar360en2026-09-11T00:00:00.000ZNCT06920511: Cognitive Rehabilitation With Virtual Reality in Parkinson Diseasehttps://www.pharmaradar360.com/article/nct06899633-multicenter-observational-descriptive-study-of-the-diagnosis-course-0e77eb58f35b55e8PharmaRadar360en2026-09-11T00:00:00.000ZNCT06899633: Multicenter, Observational, Descriptive Study of the Diagnosis, Course and Treatment of Patients With SLE in Routine Practice in Kazakhstan: a Registry Study With Retrospective and Prospective Components.https://www.pharmaradar360.com/article/nct06681662-ephedrine-for-reducing-onset-time-of-rocurinium-in-elderly-patients-b768979f5853708dPharmaRadar360en2026-09-11T00:00:00.000ZNCT06681662: Ephedrine for Reducing Onset Time of Rocurinium in Elderly Patientshttps://www.pharmaradar360.com/article/nct06562803-efficacy-and-safety-of-cytokine-adsorption-and-plasma-exchange-in-pa-06361ddfe1bd13c4PharmaRadar360en2026-09-11T00:00:00.000ZNCT06562803: Efficacy and Safety of Cytokine Adsorption and Plasma Exchange in Patients With ACLF and Sepsishttps://www.pharmaradar360.com/article/nct06429761-phase-4-study-to-assess-the-safety-of-trastuzumab-deruxtecan-in-indi-8c232c7e7eca860cPharmaRadar360en2026-09-11T00:00:00.000ZNCT06429761: Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patientshttps://www.pharmaradar360.com/article/nct06292845-ex-vivo-tumor-visualization-and-resection-margin-assessment-using-to-458aae9925424cc4PharmaRadar360en2026-09-11T00:00:00.000ZNCT06292845: Ex Vivo Tumor Visualization and Resection Margin Assessment Using Topically Applied Fluorescent Imaging Agentshttps://www.pharmaradar360.com/article/nct06200246-cardio-vascular-energy-transfer-and-ventriculo-arterial-coupling-in-ef954c69ea799072PharmaRadar360en2026-09-11T00:00:00.000ZNCT06200246: Cardio-vascular Energy Transfer and Ventriculo-arterial Coupling in Heart Failurehttps://www.pharmaradar360.com/article/nct06200155-psilocybin-assisted-psychotherapy-in-patients-with-advanced-cancer-o-0d46d0afc351195aPharmaRadar360en2026-09-11T00:00:00.000ZNCT06200155: Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapyhttps://www.pharmaradar360.com/article/nct05985954-open-label-phase-1b-study-of-ulixertinib-and-cetuximab-or-ulixertini-f33b527d6a3e103aPharmaRadar360en2026-09-11T00:00:00.000ZNCT05985954: Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapyhttps://www.pharmaradar360.com/article/nct05924464-group-preconception-care-for-fertility-patients-592f3e630e81ffb8PharmaRadar360en2026-09-11T00:00:00.000ZNCT05924464: Group Preconception Care for Fertility Patientshttps://www.pharmaradar360.com/article/nct05920356-a-study-evaluating-sotorasib-platinum-doublet-combination-versus-pem-b413c482bc01e9dcPharmaRadar360en2026-09-11T00:00:00.000ZNCT05920356: A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)https://www.pharmaradar360.com/article/nct05885555-a-study-of-ianalumab-vay736-in-patients-with-primary-immune-thromboc-0ecf7df0b9c75450PharmaRadar360en2026-09-11T00:00:00.000ZNCT05885555: A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapieshttps://www.pharmaradar360.com/article/nct05630794-testing-for-safety-and-colorectal-cancer-preventive-effects-of-onc20-79ca405eef852ea9PharmaRadar360en2026-09-11T00:00:00.000ZNCT05630794: Testing for Safety and Colorectal Cancer Preventive Effects of ONC201https://www.pharmaradar360.com/article/nct05206357-study-of-the-adverse-events-and-change-in-disease-state-of-pediatric-2875f81dc33b08abPharmaRadar360en2026-09-11T00:00:00.000ZNCT05206357: Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamabhttps://www.pharmaradar360.com/article/nct05201248-a-study-to-evaluate-adverse-events-and-change-in-disease-activity-of-7f89db7d619c8711PharmaRadar360en2026-09-11T00:00:00.000ZNCT05201248: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphomahttps://www.pharmaradar360.com/article/nct05081609-a-study-to-investigate-safety-and-tolerability-of-transcon-il-2-alon-57848da0e56e142cPharmaRadar360en2026-09-11T00:00:00.000ZNCT05081609: A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancieshttps://www.pharmaradar360.com/article/nct05019885-the-efficacy-of-a-subanesthetic-doses-of-iv-ketamine-in-the-treatmen-87333c25d030c5ebPharmaRadar360en2026-09-11T00:00:00.000ZNCT05019885: The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsyhttps://www.pharmaradar360.com/article/nct04787848-chronic-widespread-pain-in-hiv-novel-mechanisms-and-therapeutics-d7b23319aa2468caPharmaRadar360en2026-09-11T00:00:00.000ZNCT04787848: Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeuticshttps://www.pharmaradar360.com/article/nct04166409-a-study-of-the-drugs-selumetinib-vs-carboplatin-and-vincristine-in-p-f4da250f1508000ePharmaRadar360en2026-09-11T00:00:00.000ZNCT04166409: A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Gliomahttps://www.pharmaradar360.com/article/nct04032470-boston-scientific-registry-of-deep-brain-stimulation-for-treatment-o-3c738a9bbf06c5fePharmaRadar360en2026-09-11T00:00:00.000ZNCT04032470: Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)https://www.pharmaradar360.com/article/nct03100149-a-study-to-evaluate-the-efficacy-of-prasinezumab-ro7046015-prx002-in-1ec734dd69af80b5PharmaRadar360en2026-09-11T00:00:00.000ZNCT03100149: A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Diseasehttps://www.pharmaradar360.com/article/nct02880618-barostim-therapytm-in-heart-failure-with-reduced-ejection-fraction-a442fc9d8a1ae147PharmaRadar360en2026-09-11T00:00:00.000ZNCT02880618: BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fractionhttps://www.pharmaradar360.com/article/nct02824471-sickle-cell-disease-biofluid-chip-technology-scd-biochip-a841f72986de811dPharmaRadar360en2026-09-11T00:00:00.000ZNCT02824471: Sickle Cell Disease Biofluid Chip Technology (SCD BioChip)https://www.pharmaradar360.com/article/nct01679132-barostim-neo-hypertension-pivotal-trial-fddc5137d692f938PharmaRadar360en2026-09-11T00:00:00.000ZNCT01679132: BAROSTIM NEO Hypertension Pivotal Trialhttps://www.pharmaradar360.com/article/nct00047996-blood-collection-for-research-related-to-certain-diseases-involving-ec5b5f5ff1528310PharmaRadar360en2026-09-11T00:00:00.000ZNCT00047996: Blood Collection for Research Related to Certain Diseases Involving Blood Vesselshttps://www.pharmaradar360.com/article/biotech-s-2026-ipos-deliver-broad-gains-through-august-5be01e38f285a85aPharmaRadar360en2026-09-10T23:40:00.000ZBiotech’s 2026 IPOs deliver broad gains through Augusthttps://www.pharmaradar360.com/article/ctt-pharmaceutical-holdings-ceo-ryan-khouri-buys-175-in-stock-ba8ba3e61a362f04PharmaRadar360en2026-09-10T23:31:00.000ZCTT Pharmaceutical Holdings CEO Ryan Khouri buys $175 in stockhttps://www.pharmaradar360.com/article/clinical-trials-new-mrna-cancer-vaccine-plus-keytruda-sharply-improves-melanoma-77a6de9d73d0071dPharmaRadar360en2026-09-10T22:14:55.000ZClinical trials: New mRNA cancer vaccine plus Keytruda sharply improves melanoma survivalhttps://www.pharmaradar360.com/article/canaccord-genuity-maintains-buy-on-helus-pharma-cuts-target-to-42-d3a308a8f221ddf5PharmaRadar360en2026-09-10T22:08:22.000ZCanaccord Genuity maintains Buy on Helus Pharma, cuts target to $42https://www.pharmaradar360.com/article/fda-withdraws-publication-of-covid-shingles-vaccine-research-findings-0c9137b444e2e92aPharmaRadar360en2026-09-10T22:07:51.000ZFDA withdraws publication of COVID, shingles vaccine research findingshttps://www.pharmaradar360.com/article/presidential-leadership-series-features-trustee-and-former-takeda-ceo-christophe-38714faec7ed3737PharmaRadar360en2026-09-10T21:57:24.000ZPresidential Leadership Series features trustee and former Takeda CEO Christophe Weberhttps://www.pharmaradar360.com/article/cpc-biotech-multiply-labs-develop-robot-ready-cell-therapy-connector-21a5a057220ff310PharmaRadar360en2026-09-10T21:54:01.000ZCPC Biotech, Multiply Labs Develop Robot-Ready Cell Therapy Connectorhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-sr-vp-chief-hr-officer-sold-shares-worth-over-2-7m-e4a012d0bc83cc78PharmaRadar360en2026-09-10T21:40:01.000ZWest Pharmaceutical Services Sr. VP & Chief HR Officer Sold Shares Worth Over $2.7Mhttps://www.pharmaradar360.com/article/west-pharmaceutical-nyse-wst-hr-chief-sells-stock-outside-a-10b5-1-plan-f09f4eb3b8e82826PharmaRadar360en2026-09-10T21:37:29.000ZWest Pharmaceutical (NYSE: WST) HR chief sells stock outside a 10b5-1 planhttps://www.pharmaradar360.com/article/european-regulators-prepare-the-pharma-industry-for-future-changes-as-legislatio-fea13585a4f31be1PharmaRadar360en2026-09-10T21:32:04.000ZEuropean Regulators Prepare the Pharma Industry for Future Changes as Legislation is Formalizedhttps://www.pharmaradar360.com/article/new-phase-2-clinical-trial-initiating-in-2027-evaluating-psilocybin-assisted-the-b453b9741c0dd011PharmaRadar360en2026-09-10T21:10:38.000ZNew Phase 2 Clinical Trial Initiating in 2027: Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorderhttps://www.pharmaradar360.com/article/david-samra-calls-for-novartis-board-shake-up-pharmexec-d325baf3d1a4dd3ePharmaRadar360en2026-09-10T21:06:46.000ZDavid Samra Calls For Novartis Board Shake-Up | PharmExechttps://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-stock-outperforms-competitors-on-strong-trading-8d201788bc6ff87cPharmaRadar360en2026-09-10T21:04:00.000ZWest Pharmaceutical Services Inc. stock outperforms competitors on strong trading dayhttps://www.pharmaradar360.com/article/krystal-biotech-at-cantor-healthcare-conference-pipeline-gains-pace-da48474dd512d462PharmaRadar360en2026-09-10T20:42:26.000ZKrystal Biotech at Cantor healthcare conference: pipeline gains pacehttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32PharmaRadar360en2026-09-10T20:26:20.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/west-pharmaceutical-nyse-wst-awards-ceo-37k-options-and-14-8k-rsus-vesting-throu-02890534117bc52aPharmaRadar360en2026-09-10T19:40:52.000ZWest Pharmaceutical (NYSE: WST) awards CEO 37K options and 14.8K RSUs vesting through 2031https://www.pharmaradar360.com/article/precision-trading-with-fortress-biotech-inc-9-375-series-a-cumulative-redeemable-7b2183f89cc3ac84PharmaRadar360en2026-09-10T19:10:02.000ZPrecision Trading with Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Risk Zoneshttps://www.pharmaradar360.com/article/committee-will-weigh-biotech-innovation-against-security-risks-6d75b2b5f7c94bf9PharmaRadar360en2026-09-10T18:42:02.000ZCommittee Will Weigh Biotech Innovation Against Security Riskshttps://www.pharmaradar360.com/article/biohaven-shares-plunge-as-fda-halts-new-enrollment-in-epilepsy-drug-trials-ba8d221d153c02a0PharmaRadar360en2026-09-10T18:41:00.000ZBiohaven Shares Plunge as FDA Halts New Enrollment in Epilepsy Drug Trialshttps://www.pharmaradar360.com/article/encoded-secures-275m-for-dravet-syndrome-gene-therapy-ac2b33bda3009e77PharmaRadar360en2026-09-10T18:37:59.000ZEncoded secures $275m for Dravet syndrome gene therapyhttps://www.pharmaradar360.com/article/fda-seeks-public-input-on-advancing-botanical-drug-development-ed74359bca572fc5PharmaRadar360en2026-09-10T18:25:00.000ZFDA seeks public input on advancing botanical drug developmenthttps://www.pharmaradar360.com/article/abbvie-declares-quarterly-dividend-260df77eb2bfb636PharmaRadar360en2026-09-10T18:25:00.000ZAbbVie Declares Quarterly Dividendhttps://www.pharmaradar360.com/article/5-best-psychedelic-stocks-for-2026-and-how-to-invest-723c0a3c104e3b21PharmaRadar360en2026-09-10T18:18:00.000Z5 Best Psychedelic Stocks for 2026 and How to Investhttps://www.pharmaradar360.com/article/chemical-structure-formula-and-name-support-written-description-of-pharmaceutica-1d77f969ae2d3e5cPharmaRadar360en2026-09-10T18:11:11.000ZChemical Structure, Formula, and Name Support Written Description of Pharmaceutical Genushttps://www.pharmaradar360.com/article/quantum-biopharma-s-lucid-ms-advances-toward-phase-2-multiple-sclerosis-trial-af-2e6eaca0773422e8PharmaRadar360en2026-09-10T17:53:05.000ZQuantum BioPharma's Lucid-MS Advances Toward Phase 2 Multiple Sclerosis Trial After FDA Clearance